Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More
Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients ... Read More
Trovagene’s Onvansertib-decitabine combination trial shows promising results
Trovagene, a California-based cancer research company, has announced the successful completion of the second dosing cohort in its Phase 1b/2 trial investigating the Onvansertib-decitabine combination ... Read More
MedGenome study suggests cancer vaccine approach for treating Lynch Syndrome
Indian genomics research and diagnostics startup MedGenome recently unveiled promising results from a study on Lynch Syndrome, suggesting a novel approach using cancer vaccines to ... Read More
Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion
German pharmaceutical powerhouse Boehringer Ingelheim has acquired Austria-based oncolytic virus developer ViraTherapeutics for €210 million, cementing its strategic pursuit of innovative, viral-based cancer immunotherapy solutions. ... Read More
AstraZeneca secures FDA approval for Lumoxiti in hairy cell leukemia treatment
AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti (moxetumomab pasudotox-tdfk), a CD22-directed cytotoxin for the ... Read More
Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer
Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, ... Read More
Merck secures EC approval for Keytruda in combination therapy for lung cancer
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination ... Read More
Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More
Twentyeight-Seven Therapeutics launches with $65m to develop RNA-modulating cancer therapies
In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been established in Cambridge with a primary focus ... Read More